MAGNEURON · Project

Magnetic Nanoparticles That Remotely Guide Stem Cells to Treat Parkinson's Disease

healthPrototypeTRL 3Thin data (2/5)

Imagine you could transplant stem cells into a patient's brain to replace damaged neurons, but once they're in there, you have no way to tell them what to do. MAGNEURON built tiny magnetic particles coated with biological signals that get inside those stem cells. By applying a magnetic field from outside the body, doctors could steer the cells — telling them where to grow and what type of neuron to become. Think of it like a remote control for cells, aimed specifically at treating Parkinson's disease.

By the numbers

EUR 3,473,026

EU funding for magnetic stem cell control research

consortium partners across Europe

countries involved (DE, FR, UK)

total project deliverables completed

The business problem

What needed solving

Stem cell therapies for Parkinson's disease face a critical control problem: once cells are transplanted into the brain, doctors cannot direct them to grow in the right direction or become the right type of neuron. This lack of control leads to unpredictable outcomes and is a major barrier to making cell replacement therapies reliable enough for clinical use.

The solution

What was built

The team built biofunctionalized magnetic nanoparticles that can be loaded into stem cells and activated by external magnetic fields to control cell signaling (specifically Wnt and neurotrophin pathways). They also delivered a device for parallelized magnetic stimulation with high-throughput assay capability, based on microfabricated micromagnets combined with micropatterning.

Audience

Who needs this

Cell therapy companies developing treatments for Parkinson's and other neurodegenerative diseasesBiotech instrument companies building cell manipulation and screening platformsPharmaceutical companies with neuroscience R&D pipelinesNanomedicine startups working on functionalized magnetic nanoparticlesUniversity hospitals with regenerative medicine programs

Business applications

Who can put this to work

Regenerative medicine and cell therapy

enterprise

Target: Cell therapy companies developing treatments for neurodegenerative diseases

If you are a cell therapy company struggling with poor control over transplanted stem cell behavior in the brain — this project developed magnetic nanoparticles that can be loaded into cells and activated by external magnetic fields to direct differentiation and growth. The consortium of 8 partners across 3 countries built and tested a device for parallelized magnetic stimulation with high-throughput assay capability, backed by EUR 3,473,026 in EU funding.

Pharmaceutical and biotech tools

mid-size

Target: Biotech companies developing high-throughput screening platforms

If you are a biotech tools company looking for new ways to control and screen cellular responses at scale — this project delivered a device for parallelized stimulation and high-throughput assay based on microfabricated micromagnets combined with micropatterning. This enables testing magnetic control of cell signaling across multiple cells simultaneously, opening a new product category in cell manipulation instruments.

Nanomedicine and drug delivery

any

Target: Nanoparticle engineering companies focused on targeted therapeutics

If you are a nanomedicine company working on functionalized nanoparticles for therapeutic applications — this project advanced the science of biofunctionalized magnetic nanoparticles that hijack intracellular signaling pathways (Wnt and neurotrophin). With 5 university partners and 2 research organizations contributing expertise in surface functionalization and cellular nanobiophysics, the platform could extend beyond neurology into other areas requiring precise cell control.

Frequently asked

Quick answers

How much would it cost to license or adopt this technology?

The project was funded with EUR 3,473,026 in EU contribution under a FET Open grant, indicating early-stage research investment. Licensing terms would need to be negotiated directly with the coordinator (Institut Curie, France). As a public research institution, they typically offer licensing or collaboration agreements.

Can this scale to industrial production?

Based on available project data, the technology is still at the research stage. The team built a device for parallelized stimulation and high-throughput assay using microfabrication, which is a step toward scalability. However, moving from lab-scale microfabricated devices to clinical-grade manufacturing would require significant additional development.

What is the intellectual property situation?

The project ran from 2016 to 2019 with 8 partners across 3 countries. IP generated under EU-funded projects typically belongs to the partner that created it, with access rights for other consortium members. Institut Curie as coordinator would be the primary contact for IP discussions.

What regulatory approvals would be needed?

Any clinical application would require full regulatory approval for both the magnetic nanoparticles (as a medical device or advanced therapy medicinal product) and the cell therapy itself. This is a long regulatory path — the project focused on the fundamental science, not regulatory preparation.

How far is this from being used in patients?

The project ended in 2019 and was classified as FET Open (Future and Emerging Technologies), meaning frontier research. The team demonstrated magnetic control of cell signaling and built a high-throughput assay device, but clinical application in Parkinson's patients would likely require another decade of preclinical and clinical development.

Can this technology be adapted for diseases other than Parkinson's?

The objective mentions cell replacement therapies for neurodegenerative diseases and injuries broadly. The core technology — magnetic nanoparticles that control intracellular signaling — is described as versatile and could potentially be applied to other conditions requiring precise control of transplanted cells.

Consortium

Who built it

The MAGNEURON consortium brings together 8 partners from 3 countries (Germany, France, UK), heavily weighted toward academia with 5 universities and 2 research organizations. Only 1 industrial partner is involved (12% industry ratio), and there are zero SMEs. This is typical of a fundamental research project — the science is strong, led by Institut Curie in France, but the path to commercialization would require bringing in pharmaceutical or biotech industry partners. For a business looking to adopt this technology, the low industry involvement means there is likely no established supply chain or commercial roadmap yet, but it also means there may be significant first-mover advantage for companies willing to invest in translating this research.

INSTITUT CURIECoordinator · FR
UNIVERSITY OF KEELE ROYAL CHARTERparticipant · UK
EFFICIENT INNOVATION SASparticipant · FR
THE UNIVERSITY OF BIRMINGHAMparticipant · UK
RUHR-UNIVERSITAET BOCHUMparticipant · DE
UNIVERSITAET OSNABRUECKparticipant · DE
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSparticipant · FR
SORBONNE UNIVERSITEthirdparty · FR

How to reach the team

Institut Curie, France — leading French cancer and biophysics research institute. Contact their technology transfer office for licensing inquiries.

Order a report on this consortium See INSTITUT CURIE profile →

Next steps

Talk to the team behind this work.

Want to explore how magnetic nanoparticle cell control could fit your R&D pipeline? SciTransfer can arrange an introduction to the MAGNEURON research team and help you evaluate the technology.

Order a report on this topic More in Health & Biomedical